Cyclin-dependent kinase 7 inhibitor THZ1 in cancer therapy
Current cancer therapies have encountered adverse response due to poor therapeutic efficiency, severe side effects and acquired resistance to multiple drugs. Thus, there are urgent needs for finding new cancer-targeted pharmacological strategies. In this review, we summarized the current understandi...
Saved in:
Main Authors: | Bin-Bin Li, Bo Wang, Cheng-Ming Zhu, Di Tang, Jun Pang, Jing Zhao, Chun-Hui Sun, Miao-Juan Qiu, Zhi-Rong Qian |
---|---|
Format: | article |
Language: | EN |
Published: |
KeAi Communications Co., Ltd.
2019
|
Subjects: | |
Online Access: | https://doaj.org/article/c65a4a41082d4663a0cc81b8d4f5703e |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Inhibitors, PROTACs and Molecular Glues as Diverse Therapeutic Modalities to Target Cyclin-Dependent Kinase
by: Sandeep Rana, et al.
Published: (2021) -
Targeting cyclin-dependent kinases for the treatment of pulmonary arterial hypertension
by: Astrid Weiss, et al.
Published: (2019) -
Cyclin-dependent kinase 9 is required for the survival of adult Drosophila melanogaster glia
by: Lynette C. Foo
Published: (2017) -
Cyclin-dependent Kinase 5: Novel role of gene variants identified in ADHD
by: Subhamita Maitra, et al.
Published: (2017) -
Susceptibility of cyclin-dependent kinase inhibitor 1-deficient mice to rheumatoid arthritis arising from interleukin-1β-induced inflammation
by: Yoshinori Takashima, et al.
Published: (2021)